A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B Vaccine

NCT04289987 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2024-02-13

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of the investigational medicinal product CVI-HBV-002.

Conditions

  • Hepatitis B, Chronic

Interventions

BIOLOGICAL

CVI-HBV-002

Investigational Product

BIOLOGICAL

Normal Saline(placebo)

Investigational Product

Sponsors & Collaborators

  • CHA Vaccine Institute Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Joon Hyeok Lee · Samsung Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-19
Primary Completion
2023-12-04
Completion
2023-12-04

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04289987 on ClinicalTrials.gov